🇺🇸 FDA
Pipeline program

Vacuna Dermatophagoides mezcla Placebo, Vacuna Dermatophagoides mezcla 3000 TBU/ml, Test de provocación nasal, Vacuna Dermatophagoides mezcla 6000 TBU/ml, Vacuna Dermatophagoides mezcla 1000 TBU/ml

APISLIT-DD-D-2025-01

Phase 2 small_molecule active

Quick answer

Vacuna Dermatophagoides mezcla Placebo, Vacuna Dermatophagoides mezcla 3000 TBU/ml, Test de provocación nasal, Vacuna Dermatophagoides mezcla 6000 TBU/ml, Vacuna Dermatophagoides mezcla 1000 TBU/ml for Allergic rhinitis/rhinoconjunctivitis caused by dust mite allergy is a Phase 2 program (small_molecule) at Advanced Accelerator Applications with 1 ClinicalTrials.gov record(s).

Program details

Company
Advanced Accelerator Applications
Indication
Allergic rhinitis/rhinoconjunctivitis caused by dust mite allergy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials